Kymriah (Tisagenlecleucel)

Kymriah is a CAR T‑cell immunotherapy that targets CD19‑positive B‑cell malignancies.

• Relapsed or refractory B‑cell acute lymphoblastic leukemia (ALL): provides targeted cellular therapy that can induce remission in patients up to 25 years of age.
• Relapsed or refractory diffuse large B‑cell lymphoma (DLBCL): offers an option for adult patients whose disease has not responded to standard treatments.
• CD19‑positive B‑cell malignancies (general): enables selective cytotoxicity against malignant B cells expressing the CD19 antigen.

• Kymriah uses the patient’s own T cells, collected by leukapheresis and genetically engineered to express a chimeric antigen receptor that binds CD19 on B‑cell malignancies. After infusion, the modified T cells expand, recognize CD19‑expressing cells, and trigger activation pathways that lead to cytokine release and direct tumor cell lysis, delivering a targeted immunologic attack.

Kymriah can be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Cytokine release syndrome: fever, hypotension, and flu‑like symptoms occurring shortly after infusion.
• Fatigue: persistent tiredness reported during the first weeks post‑treatment.
• Nausea: mild to moderate gastrointestinal upset.
• Headache: transient cranial discomfort.

Serious or Rare Side Effects

• Neurotoxicity: encephalopathy, seizures, or aphasia that may require intensive monitoring.
• Severe infections: opportunistic bacterial, viral, or fungal infections due to immune suppression.
• Prolonged cytopenias: lasting low blood counts that increase bleeding or infection risk.
• Tumor lysis syndrome: rapid tumor breakdown leading to metabolic disturbances.

Clinicians should observe several precautions when administering Kymriah to minimize risks.

• Patient monitoring: observe for cytokine release syndrome and neurotoxicity during the first 30 days post‑infusion.
• Infection control: screen for active infections and avoid live vaccines before and after therapy.
• Cardiac assessment: evaluate baseline cardiac function as hypotension and arrhythmias may occur.
• Hematologic surveillance: regularly check blood counts to detect prolonged cytopenias.
• Store at 2-8°C: keep the cell product refrigerated, protect from light, do not freeze or shake.

Kymriah may interact with other agents that affect immune function or cytokine activity.

Major Interactions (Avoid)

• Live attenuated vaccines: administration can cause uncontrolled infection due to immunosuppression.
• Concurrent strong immunosuppressants: may exacerbate infection risk and diminish therapeutic efficacy.
• High‑dose corticosteroids during infusion: can blunt CAR T‑cell expansion and reduce response.

Moderate Interactions (Monitor Closely)

• Antimicrobial prophylaxis agents: adjust dosing to avoid overlapping toxicities.
• Cytokine‑targeting therapies (e.g., tocilizumab): may be required to manage cytokine release syndrome but should be coordinated with the treatment team.
• Other cellular therapies: schedule spacing to prevent overlapping immune activation.